Latest Muscle relaxants Stories
Psychopharmaceutical use has risen over recent years. This is fact, but what is not clear is the reason why. Researchers from four Madrid-based health centers have shown that family conflict is not a significant factor.
The genes that play a role in adolescent insomnia are the same as those involved in depression and anxiety, according to a research abstract that will be presented on Monday, June 8.
Drug-facilitated sexual crimes are increasing. The Bonn Institute for Forensic Medicine has recorded that the number of examinations on the use of intoxicants in sexual offences within their catchment area increased 10-fold between 1997 and 2006.
DETROIT, May 8 /PRNewswire/ -- Henry Ford Hospital is embarking on an unusual study intending to reduce brain damage or death of patients resulting from prolonged seizures before arriving at the hospital. But because the patients are unconscious during the seizure, they will not be able to provide informed consent to participate in the study.
The risk of being involved in a traffic accident with personal injury is significantly higher among codeine users than non-users. However, sporadic or moderate use of codeine alone does not carry an increased risk, according to a newly published study from the Norwegian Institute of Public Health.
A study of insomnia patients suggests it is a persistent condition that is hard to shake.
About three-fourths of individuals with insomnia report experiencing the condition for at least one year and almost half experience it for three years, according to a report in the March 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
The largest proportions of all insomnia-related expenses are attributed to lost job productivity, absences from work and alcohol used as a sleep aid.
KENILWORTH, N.J., Oct. 28 /PRNewswire-FirstCall/ -- Schering-Plough Corp., today announced that a study published in the November 2008 issue of the medical journal, Anesthesiology (Vol. 109, No.
AACHEN, Germany and CAMBRIDGE, UK, Sept. 22, 2008 (GLOBE NEWSWIRE) -- The biopharmaceutical company PAION AG (ISIN DE000A0B65S3) (Frankfurt:PA8) (London AIM: PAI) today announces that its Phase I study with its sedative CNS 7056 has progressed to the dose levels that induce pronounced sedation.
- A trick or prank.